Previous 10 | Next 10 |
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...
2023-03-08 08:50:15 ET Summary Anavex seems to have effectively handled the Rett syndrome endpoint issues. A future publication should also throw more light on the AD data. The company is progressing well with its trials. I covered Anavex ( AVXL ) on January 12, ...
2023-03-06 20:21:53 ET Shares of Anavex Life Sciences (NASDAQ: AVXL) rose 12.4% in February, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech's stock closed at $10.87 in January, then rose to a high of $11.93 on Feb. 7, the day th...
2023-03-04 13:45:00 ET A record $138B was invested by the 15 largest pharmaceutical companies in 2022, a staggering 43% increase since 2017, according to an IQVIA report. That $138B accounted for ~19% of these companies' overall sales. IQVIA also found that although biopharma in...
Anavex Life Sciences (NASDAQ: AVXL) is a small-cap stock with big ambitions. It has a potential Alzheimer's treatment that fared well in recent trials and could be a game-changer for the business. But the company remains unprofitable, and the stock is heavily shorted and volatile. Is An...
Legit short squeezes are fairly rare. But when they do occur, shareholders of heavily shorted equities can generate enormous returns on capital in an exceedingly short period. Which under-the-radar equity stands out as a top short-squeeze candidate right now? The developmental biotech A...
Summary Anavex Life Sciences recently reported their Q1 2023 earnings that revealed a beat on EPS and a robust cash position that should fund the company for the next four years. The company updated investors on ANAVEX 2-73 in Alzheimer's and publicized that they “plan to submit ...
Shares of the clinical-stage biopharma Anavex Life Sciences (NASDAQ: AVXL) rose by a stately 17.4% over the course of January, according to data provided by S&P Global Market Intelligence . The biopharma's shares have been charging higher of late thanks to positive late-stage resu...
The shares of Anavex Life Sciences ( NASDAQ: AVXL ) reached the highest level since early December on Tuesday after the Alzheimer's drug developer announced financials for Q1 fiscal 2023 highlighting its near-term catalysts. Anavex ( AVXL ), based in New York, reported ~$143.6...
Anavex Life Sciences Corp. (AVXL) Q1 2023 Earnings Conference Call February 7, 2023, 08:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants So...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...